ClinicalTrials.gg
RecruitingNCT05507242UPSTREAM-COPDUpdated Aug 21, 2024

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD

A Phase 2 interventional study of Tezepelumab and Placebo in COPD, COPD Exacerbation and COPD Bronchitis, sponsored by Asger Sverrild. Recruiting at 2 sites in 2 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Asger Sverrild · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 243 studies in Pulmonary Disease, Chronic Obstructive with a site in Denmark — 33 open to participants now, 42 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Denmark.

Planned enrollment
147th of 209
80 · median 182
Started
2022
with 7 others
Phase 2
25 of 243
4 open now
Primary completion
2025-12
later than 7 of 41 live
Registered
185th of 243
by date

Among the 243 studies in Pulmonary Disease, Chronic Obstructive with a site in Denmark, this one is the 147th largest by planned enrollment of the 209 interventional ones that give a count, is one of 8 that started in 2022, is one of 25 in phase 2, reaches primary completion later than 7 of the 41 other live ones, and was the 185th registered.

Pulmonary Disease, Chronic Obstructive

5,522 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

33 of the 243 studies in Pulmonary Disease, Chronic Obstructive with a site in Denmark are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 243 studies in Pulmonary Disease, Chronic Obstructive with a site in Denmark, or all of them as a file.
02

Study summary

A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.

Read the detailed description

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD on LABA+LAMA±ICS with ≥ 1 exacerbation the past 12 months. Approximately 80 subjects will be randomized to receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 20-week treatment period.

03

Conditions studied

  • COPD
  • COPD Exacerbation
  • COPD Bronchitis
  • Airway Disease
  • Immune System Disorder

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • A diagnosis of (according to GOLD (GOLD 2021 Report))
  • ≥ 10 packyears smoked (current or ex-smokers)
  • Age 40 years or older
  • Postbronchodilator ≥ 30% predicted (and ≥ 1.0L) and \< 80% predicted
  • Maintenance treatment with LAMA+LABA±ICS (stable dose) for at least 3 months prior to V1
  • ≥1 prednisolon and/or antibiotic treated exacerbation in the past 12 months
  • Subjects must demonstrate acceptable inhaler and spirometry techniques during screening (as evaluated and in the opinion of study site staff)
  • Subjects must demonstrate ≥ 70% compliance with daily inhalers during the screening/run-in
  • Females of who are sexually active with a nonsterilized male partner must use a highly effective method of from the time informed consent is obtained and must agree to continue using such precautions through Week 20 of the study; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or (defined as 12 months with no menses without an alternative medical cause).

Exclusion criteria

Exclusion Criteria:

  • Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the product or reduce the subject's ability to participate in the study. Subjects with well-controlled comorbid disease (eg, hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible.
  • Any concomitant respiratory disease that in the opinion of the investigator will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., cystic fibrosis, pulmonary fibrosis, aspergillosis, active tuberculosis).
  • Current asthma
  • Lung volume reduction surgery for
  • Exacerbation requiring oral or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period
  • Any use of home oxygen therapy
  • Any abnormal findings in hematology or clinical chemistry (laboratory results from Visit 1), physical examination, vital signs during the screening, which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study
  • History of cancer: Subjects who have had basal cell carcinoma or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1. Subjects who have had other are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.
  • Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 4 weeks prior to Visit 1 or during the screening period
  • A positive (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history
  • Positive surface antigen, or virus antibody serology at screening, or a positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll.
  • History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation.
  • History of any known primary immunodeficiency disorder excluding asymptomatic selective immunoglobulin A or IgG subclass deficiency.
  • Active tuberculosis or history of untreated latent tuberculosis
  • History of anaphylaxis to any biologic therapy.
  • Use of medication (eg, methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1.
  • Receipt of any of the following within 30 days prior to Visit 1: immunoglobulin or blood products, or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives prior Visit 1, whichever is longer.
  • Receipt of any marketed or investigational biologic agent within 4 months or 5 half- lives prior to Visit 1, whichever is longer.
  • Pregnant, breastfeeding or lactating females
  • History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
  • Planned surgical procedures requiring general anesthesia or in-patient status for > 1 day during the conduct of the study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Concurrent enrollment in another clinical study involving an investigational treatment.
  • Receipt of any live or attenuated vaccines within 15 days prior to Visit 1.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab subcutaneous injection

    Biological: Tezepelumab

  • Placebo comparator
    Placebo

    Placebo subcutaneous injection

    Other: Placebo

Interventions

  • BiologicalTezepelumab

    Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously

  • OtherPlacebo

    Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of tezepelumab on eosinophilic bronchial mucosal tissue inflammation

    The change, expressed as ratio, in eosinophil cell counts per mm2 from baseline to week-20

    Time frame: 20 weeks

Secondary outcomes

  1. To evaluate the effect of tezepelumab on neutrophilic bronchial mucosal tissue inflammation

    The change, expressed as ratio, in neutrophil cell couts per mm2 from baseline to week-20

    Time frame: 20 weeks

  2. To evaluate the effect of tezepelumab on mast cell bronchial mucosal tissue inflammation

    The change, expressed as ratio, in mast cell couts per mm2 from baseline to week-20

    Time frame: 20 weeks

  3. To evaluate the effect of tezepelumab on CD4+ cell bronchial mucosal tissue inflammation

    The change, expressed as ratio, in CD4+ cell couts per mm2 from baseline to week-20

    Time frame: 20 weeks

  4. To evaluate the effect of tezepelumab on CD8+ cell bronchial mucosal tissue inflammation

    The change, expressed as ratio, in CD8+ cell couts per mm2 from baseline to week-20

    Time frame: 20 weeks

  5. To evaluate the effect of tezepelumab on macrophage cell bronchial mucosal tissue inflammation

    The change, expressed as ratio, in macrophage cell couts per mm2 from baseline to week-20

    Time frame: 20 weeks

07

Study locations

2 of 2 sites recruiting
  • Research site
    Copenhagen, 2400, Denmark
    Recruiting
  • Research site
    Leicester, LE3 9QP, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2025, 38 months after the start.

Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 38 months is close to that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2022
First posted
Aug 18, 2022
StartActual
Oct 25, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05507242
Lead sponsor
Asger Sverrild
Collaborators
AstraZeneca, University Hospitals, Leicester
Responsible party
Asger Sverrild (MD, PhD, Clinical Associate Professor, Bispebjerg Hospital) — Sponsor-investigator
First posted
Aug 18, 2022
Start date
Oct 25, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 21, 2024

Study contacts

Kristoffer Norheim, PhD
Contact
kristoffer.norheim@regionh.dk
+4542831337
Asger Sverrild, MD, PhD
Contact
asger.sverrild@regionh.dk
Asger Sverrild, MD, PhD
principal investigator · Bispebjerg Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion